These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29737248)

  • 41. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of angiotensin converting enzyme (
    Ramanathan G; Ghosh S; Elumalai R; Periyasamy S; Lakkakula BV
    Indian J Med Res; 2016 Jun; 143(6):748-755. PubMed ID: 27748299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?
    Pisani A; Riccio E; Bruzzese D; Sabbatini M
    BMC Nephrol; 2018 Oct; 19(1):282. PubMed ID: 30348113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dietary Care for ADPKD Patients: Current Status and Future Directions.
    Carriazo S; Perez-Gomez MV; Cordido A; García-González MA; Sanz AB; Ortiz A; Sanchez-Niño MD
    Nutrients; 2019 Jul; 11(7):. PubMed ID: 31336917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of PPARα in autosomal dominant polycystic kidney disease.
    Lakhia R
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):432-438. PubMed ID: 32427692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy.
    Tsai YC; Teng IL; Jiang ST; Lee YC; Chiou YY; Cheng FY
    Adv Healthc Mater; 2019 Mar; 8(5):e1801358. PubMed ID: 30672150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease.
    Xu Y; Li A; Wu G; Liang C
    Curr Gene Ther; 2017; 17(1):43-49. PubMed ID: 28494735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease.
    Cox A; Tung M; Li H; Hallows KR; Chung EJ
    SLAS Technol; 2023 Aug; 28(4):223-229. PubMed ID: 36804177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulating inflammation with interleukin 37 treatment ameliorates murine Autosomal Dominant Polycystic Kidney Disease.
    Zylberberg AK; Cottle DL; Runting J; Rodrigues G; Tham MS; Jones LK; Cumming HE; Short KM; Zaph C; Smyth IM
    Kidney Int; 2024 Apr; 105(4):731-743. PubMed ID: 38158181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights.
    Capelli I; Lerario S; Ciurli F; Berti GM; Aiello V; Provenzano M; La Manna G
    Expert Opin Investig Drugs; 2024 May; 33(5):469-484. PubMed ID: 38618918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Practical approach to patient therapy affected by Autosomal Dominant Autosomic Polycystic Kidney Disease].
    Esposito C; La Milia V; Altobelli C; Cerutti R; Manunta P; Dallera N; Piscopo G; Magistroni R
    G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Smith KA; Thompson AM; Baron DA; Broadbent ST; Lundstrom GH; Perrone RD
    Am J Kidney Dis; 2019 Apr; 73(4):533-541. PubMed ID: 30600104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.
    Benz EG; Hartung EA
    Pediatr Nephrol; 2021 Sep; 36(9):2639-2658. PubMed ID: 33474686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T; Chapman AB; Brosnahan GM; Edelstein CL; Johnson AM; Schrier RW
    Am J Kidney Dis; 2000 Mar; 35(3):427-32. PubMed ID: 10692268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
    Wüthrich RP; Serra AL
    Transplant Proc; 2009; 41(6 Suppl):S18-20. PubMed ID: 19651290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
    Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
    BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insights into autosomal dominant polycystic kidney disease by quantitative mass spectrometry-based proteomics.
    Diedrich B; Dengjel J
    Cell Tissue Res; 2017 Jul; 369(1):41-51. PubMed ID: 28432464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel hits for autosomal dominated polycystic kidney disease (ADPKD) targeting derived by
    Nejabat M; Hadizadeh F; Nejabat M; Rajabi O
    J Biomol Struct Dyn; 2024; 42(2):885-902. PubMed ID: 37029756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.